Vice President
Current• Developed and continue to evolve the Radiopharmaceutical Therapy (RPT) Strategy for BMS. This has contributed to acquisition of Rayze Bio in 2024 and equity investments in Aktis and Ratio Therapeutics• Instrumental in enhancing our CELMoD protein degradation strategy via several multi-year collaborations with Evotec and BMS’s strategy for moving beyond cereblon in protein homeostasis • Collaborated with the BMS equity team to define emerging areas and strategic biotech investments e.g. Envisagenics, Exscientia, Charm, Cleave, Ikena, Repare, Light Horse, Be Bio, Metagenomi• Engage with over 25 venture capital groups yearly, including Limited Partner (LP) positions. Represent BMS at JPM investor conference.• Played a crucial role in identifying and establishing >30 multiyear collaborations supporting the development of programs from platform to asset. These efforts led to several drug approvals and numerous molecules entering the BMS pipeline:- Biotech & VC collaborations include: Agios, Epizyme, Forma Therapeutics, Ikena, Northern Biologics, Adimab, Molecular Templates, Nabla Bio, Exscientia, Schrodinger, Charm, Terray, Skyhawk, Repare, Volastra, H3 Biomedicine, Envisagenics, Darwin Health, Tempus, Scenic, Evotec Proteomics 1.0 & 2.0, VantAI, A-Alpha, Synthex, Amphista, two incubators with Versant Ventures (Highline in NYC, Blueline in Toronto)- Academic collaborations: Celgene’s Recombinant Antibody Network (UCSF, Univ. of Chicago & Univ. of Toronto), Moffitt Cancer Center, Tsinghua University (China), and Celgene’s Four Cancer Consortium (Columbia, Mt. Sinai, UPenn, JHU Medical Schools)• Serve on numerous Joint Scientific Committees (JSC) working to build positive relationships with biotechs, problem solve, ensure program success and alignment with internal R&ED strategy• Sponsor for application of Large Language Models in Research at BMS• Board Observer: Ceptur (previous), Envisagenics (current)
